Fumitaka Mori is listed as a director on 3 SEC Form D filings by 1 issuer between Sep 2018 and Jan 2021: ENB Therapeutics, Inc. (New York, NY — biotechnology — 2018–2021; $8.09M reported sold to 17 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Albert Sokol (3 shared filings), Barbara Schilberg (3 shared filings) and Sumayah Jamal (3 shared filings).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Fumitaka. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 3 public filings for Fumitaka Mori and found 2 differences: No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.